RAEM

REVISTA ARGENTINA DE ENDOCRINOLOGÍA Y METABOLISMO

Trabajo Original



Soybean oil prevents hypothalamic N3 fatty acid composition but does not prevent peripheral tissue fatty acid disturbance in rats

WATANABE RLH¹, BOLDARINE VT¹, PEDROSO AP¹, TELLES MM¹, DORNELLAS APS², WANG Y³, BUENO AA⁴*, RIBEIRO EB¹

¹Department of Physiology, Paulista School of Medicine, Universida de Federal de São Paulo, São Paulo, Brazil.

INFORMACIÓN DEL ARTÍCULO

Historia del artículo: Recibido: 25 de agosto de 2021 Revisión: 22 de noviembre de 2021 Aceptado: 1 de diciembre de 2021

Palabras clave: ácido linoleico ácido alfa-linolénico aceite de soja aceite de pescado hipotálamo tejido adiposo

RESUMEN

Los ácidos linoleico (LA) y alfa-linolénico (ALA) son los únicos ácidos grasos poliinsaturados (PUFA) N6 y N3 verdaderamente esenciales, y los precursores de los ácidos araquidónico y docosahexaenoico (DHA), los PUFAs más prevalentes en el cerebro de mamíferos. Las principales fuentes dietéticas de N6 son los aceites vegetales y la carne roja, y las principales fuentes de DHA incluyen el pescado. Esta limitación se hace evidente al considerar las dietas típicas occidentalizadas. Además, las fuentes marinas se encuentran actualmente amenazadas debido a la sobrepesca y la falta de sostenibilidad. En el presente estudio investigamos la composición de ácidos grasos (FA) de suero, hipotálamo, hígado y tejido adiposo blanco (WAT) de ratas alimentadas con dietas enriquecidas con aceite de pescado (FO) o aceite de soja (SO). Mientras que FO contiene abundante DHA, SO proporciona pequeñas cantidades de ALA, junto con su importante contenido de LA. Quince ratas Wistar de 35 días fueran alimentadas con una dieta control ó enriquecida con FO (FOD) o SO (SOD) durante 8 semanas. Las ratas fueran sacrificadas y se extrajo sangre, hipotálamo, hígado y WAT, y se analizó la composición de FA mediante cromatografía de gases. FOD aumentó el contenido de N3 y SOD aumentó el contenido de N6 en todos los tejidos. Sin embargo, la SOD aumentó significativamente el DHA en el hipotálamo y el suero, un resultado que no se observó en otros tejidos de la SOD. Mientras que las ratas SOD desarrollaron obesidad, las FOD no lo hicieron. Las ratas SOD desarrollaron obesidad y desequilibrio periférico de N6/ N3, pero su contenido hipotalámico de N3 aumentó. Estos resultados corroboran aún más la biomagnificación y la captación preferencial de FA por el cerebro. Se necesitan estudios adicionales para investigar cómo las dietas con desequilibrio de nutrientes afectan aún más el metabolismo cerebral.

²Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.

³Department of Medicine, Institute of Reproductive and Developmental Biology, Imperial College London, London, United Kingdom. ⁴School of Science and the Environment, University of Worcester, Worcester, England.

^{*}Autor para correspondencia: valtertadeuboldarine@gmail.com

ABSTRACT

Keywords: Linoleic acid alpha-linolenic acid soybean oil fish oil hypothalamus adipose tissue

Linoleic (LA) and alpha-linolenic (ALA) acids are the only truly essential N6 and N3 polyunsaturated fatty acids (PUFAs), and the precursors of arachidonicand docosahexaenoic (DHA) acids, the most prevalent PUFAs in the mammalian brain. Whilst main dietary sources of N6 are plant oils and red meat, the main sources of DHA include seawater fish. This issue becomes apparent when considering typical westernised diets. Furthermore, marine sources are currently threatened due to overfishing and no sustainability. Here we investigated the serum, hypothalamus, liver and white adipose tissues (WAT) fatty acid (FA) composition of rats fed a diet enriched with either fish oil (FO) or soybean oil (SO). Whilst FO contains abundant DHA, SO provides small amounts of ALA, alongside its important LA content. Fifteen 35-day old Wistar rats were fed a control chow, or a diet enriched with FO (FOD) or SO (SOD) for 8 weeks. Rats were sacrificed, trunk blood collected, hypothalamus, liver and WAT dissected, and their FA composition analysed by gas chromatography. FOD increased N3 content and SOD increased N6 content in all tissues. However, SOD significantly increased DHA in hypothalamus and serum, a result not observed in other SOD tissues. Whilst the SOD rats developed obesity, the FOD did not. SOD rats developed obesity and imbalanced N6/N3 peripherally, but their hypothalamic N3 content was increased. Such results further corroborate biomagnification and the preferential FA uptake by the brain. Additional studies are necessary to investigate how nutrient-unbalanced diets further affect brain metabolism.

INTRODUCTION

Fatty acids (FA) constitute integral components of the cell structure, contribute to the modulation of the cell cycle and cell signalling, and in a way or another participate in virtually all homeostatic processes (1,2,3). Linoleic acid (LA) and alphalinolenic acid (ALA) are the only truly essential N6 and N3FAs, as human cells cannot insert double bonds at carbons beyond C9 in the fatty acid chain⁽⁴⁾. LA and ALA are the substrate for elongases and desaturases, enzymes that indiscriminately elongate and desaturate LA and ALA to their respective 20 carbons-product arachidonic acid (AA) and eicosapentaenoic acid (EPA)⁽⁵⁾. In a subsequent complex set of enzymatic reactions, AA and EPA are metabolised to N6-docosapentaenoic acid (N6-DPA) and docosahexaenoic acid (DHA)^(5,6). Even though LA and ALA are the only truly essential FAs, AA and DHA are considered as conditionally essential FAs because humans cannot synthetize them in enough amounts to attend metabolic demands (5,6,7,8).

Different areas of the human central nervous system show slightly different fatty acid composition, but in all areas, AA is the most abundant N6, whilst DHA is the most abundant N3. Makrides and colleagues found in the frontal cortex of breastfed infants (aged 2 to 48 weeks) 10.9% AA and 8.5% DHA⁽⁹⁾.

Fraser and colleagues found in the frontal cortex of aged non-demented individuals (aged 79.2 ± 9.6) 8.67% AA and 15.42% DHA⁽¹⁰⁾. Small variations may occur between individuals, attributed mostly to their long-term diets, but overall the brain is relatively protected during periods of nutritional deficiencies. We previously demonstrated that male Wistar rats fed a lard-rich diet for 8 weeks showed dramatic AA and DHA deficits in liver and white adipose tissue whilst their serum and hypothalamic AA and DHA levels remained similar to the ones of control rats⁽¹¹⁾.

The main dietary sources of N6 FA in the typical westernised diet are red meat and plant oils, mainly palm oil, sunflower oil, corn oil, rapeseed oil and soybean oil $^{(12,13,14,15)}$. Those oils are major sources of LA, but soybean oil is the only one amongst those five oils featuring modest levels of ALA $^{(16,17)}$. China, United States, Brazil and India are the four largest global consumers of soybean oil, with a combined estimated consumption of over 3.9×107 metric tons in $2019^{(18)}$.

Interestingly, when considering the total population of those countries⁽¹⁹⁾ and the calculated soybean oil consumption per capita, Brazilians are amongst largest consumers of soybean oil globally. Brazil is the second largest producer of soybean globally, and Argentina is the second largest producer within

Mercosur. Among the ten largest soybean producers globally, four are in South America: Brazil, Argentina, Paraguay and Bolivia⁽²⁰⁾. Such finding is further added to the fact that soybean oil is the most affordable plant oil in Brazil⁽²¹⁾, a factor of major significance for lower income social classes.

The main dietary sources of EPA and DHA are seafood and seawater fish, but it is widely accepted that westernised societies often do not consume enough fish^(22,23,24). Two issues of paramount importance complicate the increase in fish intake: fish is relatively more expensive than meat⁽²⁵⁾, a major factor for individuals within the lower income brackets. Furthermore, due to the total global demand, fish consumption is at its historical high levels, whilst fish stocks are at dramatic, unprecedented low levels⁽²⁶⁾. Fishing is no longer a commercially sustainable activity^(27,28,29).

Due to the many difficulties associated with fish intake, associated with a westernised culture and lifestyle that favours red meat consumption, an imbalanced N6/N3 ratio is unavoidable^(30,31). Low N3 diets are positively associated with increased risk of metabolic diseases such as cardiovascular disease, diabetes, and others^(32,33,34). Several clinical trials have been conducted recently on flaxseed oil^(35,36) and walnut oil^(37,38), important plant sources of ALA. One of the difficulties associated with walnut and flaxseed oils, however, refers to affordability, as those oils are far more expensive than soybean oil.

As soybean oil is a highly consumed plant oil, and it presents the best ALA content amongst the most affordable plant oils, it becomes imperative to further explore and investigate the effects of soybean oil supplementation upon tissue fatty acid metabolism. The aim of the present study was to investigate the effects of an energy dense, soybean oil-enriched diet for eight weeks upon the fatty acid profile of hypothalamus, serum, liver, epidydimal, retroperitoneal and mesenteric white adipose tissue of male Wistar rats.

METHODS

Animal model

This study received ethical approval from the Research Ethics Committee of the Universida de Federal de Sao Paulo, Brazil. Institutional guidelines for the care and use of our animals have been strictly followed throughout. The principles of this study have been guided by the 'Three R's' of Animal Welfare in Research: 'Replacement, Reduction and Refinement' (39). We have used the smallest number of rats possible to obtain enough reliable data to observe an effect that could be attributed to the diet, therefore answering the research question.

Fifteen male Wistar rats, weaned on the 21st day of life, were obtained from CEDEME (Centro de Desenvolvimento de Modelos Experimentais para Medicina e Biologia, Brazil), and housed in the animal house of the Division of Nutrition Physiology, Sao Paulo Federal University, under controlled lighting (12 hours light/dark cycle, lights on at 6:00) and

temperature ($22 \pm 1^{\circ}$ C), with ad libitum access to standard rat chow (Nuvilab CR-1, Nuvital Nutrientes SA, Colombo, PR, Brazil) and water. After two weeks acclimatization, the rats were randomised into three groups of five rats each, and fed the standard chow (Ctrl) or a diet enriched with fish oil (FOD) (Campestre Óleos Vegetais, São Bernardo do Campo, Brazil) or soybean oil (SOD) (Campestre Óleos Vegetais, São Bernardo do Campo, Brazil) ad libitum for 8 weeks, as detailed below.

Diet

The diets were prepared following method previously described by our group⁽¹⁾. Briefly, standard rat chow was ground and enriched with 20% fish oil or soybean oil (w/w), 10% sucrose (w/w) (União Refinado, São Paulo, Brazil), 20% casein (w/w) (Labsynth, Diadema, Brazil) and 0.02% (w/w) butylated hydroxytoluene (BHT) (Merck, Brazil). The mixture was mechanically homogenised with the addition of lukewarm water and passed through a milling machine to produce pellets, which were dried in a forced ventilation oven at 60°C for 24h. The standard rat chow energy content was 2.8 kcal/g, whilst the oil enriched diets were 4.1 kcal/g. The fatty acid composition of the fish oil and soybean oil utilized in this study, as well as the oil-enriched diets, were determined by gas chromatography following protocol described below. Oil and diet fatty acid results are presented in Table 1.

Tissue analyses

At the end of the 8th week dietary intervention period, all rats were sacrificed by decapitation under mild sedation in ethyl ether after overnight fast. Trunk blood was collected and serum obtained by centrifugation. Retroperitoneal (RET), epididymal (EPI) and mesenteric (MES) fat pads, hypothalamus and liver were dissected and weighted. A well-trained researcher performed the hypothalamic dissection to ensure accuracy and precision. All samples were stored at -80°C until analysis.

Total lipids were extracted from the Ctrl diet, FOD diet, SOD diet, as well as from serum, hypothalamus, liver, RET, EPI and MES, as described previously⁽¹¹⁾. Briefly, samples were homogenized in hexane / isopropanol (3:2 v/v) (Sigma, St Louis, MO) containing 0.01% BHT, and washed with chloroform / methanol / water (2:1:1 v/v/v) (Sigma, St Louis, MO). The samples were centrifuged, and the organic layer obtained was evaporated under oxygen-free nitrogen (OFN). Total lipids were partitioned again in chloroform / methanol / water solution (8/4/3 v/v/v). The resulting total lipid extracts were dried under OFN and kept in air-tight tubes under OFN until analysis.

FA analysis of the lipid extracts, as well as of the fish oil and the soybean oil used in this study, was performed as standardized previously⁽⁴⁰⁾. Briefly, FA methyl esters (FAME) were obtained by heating the samples with 15% acetyl chloride in anhydrous 99.8% methanol (Sigma-Aldrich, Germany) in a sealed glass tube at 70°C for 3 hours under OFN. The reaction was stopped by adding 5% NaCl (Fisher Scientific, England) solution at room temperature. FAMEs were extracted with petroleum ether containing 0.01% BHT, any remaining acid neutralized with 2%

potassium bicarbonate and any remaining water removed with anhydrous sodium sulphate. FAMEs were separated by gas chromatography with flame ionization detector (Fisons Instruments, Milan, Italy) fitted with a capillary column (BPX70, 60 m x 0.32 mm x 0.25 μ m, Thames Restek, UK).

Table 1. Fatty acids standards used for determination of retention time and identification of fatty acid methyl esters.

F.A.M.E. Mix, C4-C24 C4:0 Methyl butyrate 4 wt. % C6:0 Methyl hexanoate 4 wt. % C8:0 Methyl decanoate 4 wt. % C10:0 Methyl decanoate 2 wt. % C11:0 Methyl dodecanoate 2 wt. % C12:0 Methyl undecanoate 2 wt. % C13:0 Methyl tryitslate 4 wt. % C14:10 Methyl myristoleate 2 wt. % C14:10 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecanoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1 Methyl palmitate 6 wt. % C17:1 Methyl palmitate 6 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 Methyl elaidate 2 wt. % C18:1n9 Methyl loleate 4 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:2n6 Methyl prinolenate 2 wt. % C18:3n3 Methyl relicosance 2 wt. % C20:0 Methyl arachidonate 2 wt. % C20:1n9 Methyl relicosance accordate 2 wt. %	Analyte	
C6:0 Methyl hexanoate 4 wt. % C8:0 Methyl ctanoate 4 wt. % C10:0 Methyl decanoate 2 wt. % C11:0 Methyl undecanoate 2 wt. % C12:0 Methyl dodecanoate 2 wt. % C13:0 Methyl tridecanoate 2 wt. % C14:10 Methyl myristate 4 wt. % C14:10 Methyl myristate 4 wt. % C14:117 Methyl perntadecanoate 2 wt. % C15:0 Methyl perntadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:17 Methyl aplmitate 2 wt. % C17:0 Methyl cis-10-pentadecenoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:119 Methyl cis-10-heptadecenoate 2 wt. % C18:10 Methyl stearate 4 wt. % C18:10 Methyl stearate 4 wt. % C18:119 Methyl claidate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C20:10 Methyl arachidate 4 wt. % C20:10 Methyl reicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-3,11,14-Ficosatrienoic acid methyl ester 2 wt. % C20:2n6 Methyl beneate 4 wt. % C20:1n9 Methyl cis-13-docosenoate 2 wt. % C20:2n6 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl tricosanoate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 4 wt. % C23:0 Methyl tricosanoate 4 wt. % C22:1n9 Methyl cis-13-bocosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl cis-13-bocosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl	F.A.M.E. Mix, 0	C4-C24
C6:0 Methyl hexanoate 4 wt. % C8:0 Methyl ctanoate 4 wt. % C10:0 Methyl decanoate 2 wt. % C11:0 Methyl undecanoate 2 wt. % C12:0 Methyl dodecanoate 2 wt. % C13:0 Methyl tridecanoate 2 wt. % C14:10 Methyl myristate 4 wt. % C14:10 Methyl myristate 4 wt. % C14:117 Methyl perntadecanoate 2 wt. % C15:0 Methyl perntadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:17 Methyl aplmitate 2 wt. % C17:0 Methyl cis-10-pentadecenoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:119 Methyl cis-10-heptadecenoate 2 wt. % C18:10 Methyl stearate 4 wt. % C18:10 Methyl stearate 4 wt. % C18:119 Methyl claidate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C20:10 Methyl arachidate 4 wt. % C20:10 Methyl reicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-3,11,14-Ficosatrienoic acid methyl ester 2 wt. % C20:2n6 Methyl beneate 4 wt. % C20:1n9 Methyl cis-13-docosenoate 2 wt. % C20:2n6 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl tricosanoate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 4 wt. % C23:0 Methyl tricosanoate 4 wt. % C22:1n9 Methyl cis-13-bocosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl cis-13-bocosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl	C4:0	Methyl butyrate 4 wt. %
C8:0 Methyl octanoate 4 wt. % C10:0 Methyl decanoate 2 wt. % C11:0 Methyl undecanoate 2 wt. % C12:0 Methyl dodecanoate 2 wt. % C13:0 Methyl tridecanoate 2 wt. % C14:0 Methyl myristate 4 wt. % C14:1n7 Methyl myristate 4 wt. % C14:1n7 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C18:1n9 Methyl stearate 4 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl olaete 4 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C20:10 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosatienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatienoic acid methyl ester 2 wt. % C20:3n3 cis-5,8,11,14,17-Eicosatienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:3n0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:3n0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:3n0 Methyl tricosanoate 2 wt. % C22:3n0 Methyl behenate 4 wt. % C22:3n0 Methyl tricosanoate 2 wt. % C22:3n0 Methyl cis-13-docosenoate		• • •
C10:0 Methyl decanoate 4 wt. % C11:0 Methyl undecanoate 2 wt. % C12:0 Methyl dodecanoate 2 wt. % C13:0 Methyl tridecanoate 2 wt. % C13:0 Methyl myristate 4 wt. % C14:0 Methyl myristate 4 wt. % C14:1n7 Methyl myristate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl palmitate 6 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitate 2 wt. % C17:0 Methyl palmitate 2 wt. % C17:1 Methyl palmitate 2 wt. % C17:1 Methyl stearate 4 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 Methyl oleate 4 wt. % C18:1n9 Methyl loleate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n6 Methyl linoleate 2 wt. % C18:3n6 Methyl v-linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl arachidate 4 wt. % C20:1n9 Methyl reciosanoate 2 wt. % C20:2n6 cis-11,14-Eicosanoate 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:1n9 Methyl arachidonate 2 wt. % C20:1n9 Methyl behenate 4 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13		•
C11:0 Methyl undecanoate 2 wt. % C12:0 Methyl dodecanoate 4 wt. % C13:0 Methyl tridecanoate 2 wt. % C14:10 Methyl myristate 4 wt. % C14:10 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl pentadecanoate 2 wt. % C16:1 Methyl pentadecanoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n Methyl palmitate 6 wt. % C17:0 Methyl pelmidecanoate 2 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 trans Methyl linoleate 2 wt. % C18:2n6t Methyl linoleate 2 wt. % C18:3n6 Methyl linoleate 2 wt. % C20:0 Methyl arachidate 2 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Ficosatienoic acid methyl ester 2 wt. % C20:3n3 cis-1,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl arachidatoate 2 wt. % C22:2n6 dethyl arachidatoate 2 wt. % C22:2n9 Methyl arachidatoate 2 wt. % C22:2n9 Methyl arachidonate 2 wt. % C22:2n9 Methyl arachidonate 2 wt. % C22:2n9 Methyl arachidonate 2 wt. % C22:2n9 Methyl tirosanoate 2 wt. % C22:2n9 Methyl behenate 4 wt. % C22:2n9 Methyl tirosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:3n6 cis-13,16-Docosadienoic acid methyl ester C2:3n7 cis-11,14-Eicosadienoic acid methyl ester C2:3n8 cis-11,14-Eicosadieno		•
C12:0 Methyl dodecanoate 4 wt. % C13:0 Methyl tridecanoate 2 wt. % C14:1 Methyl myristate 4 wt. % C14:1n7 Methyl myristate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl pentadecanoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitate 2 wt. % C17:1 Methyl palmitate 2 wt. % C17:0 Methyl heptadecanoate 2 wt. % C18:1 Methyl stearate 4 wt. % C18:1 Methyl stearate 4 wt. % C18:1n9 Methyl stearate 4 wt. % C18:1n9 Methyl inolealadate 2 wt. % C18:2n6t Methyl jinolealadate 2 wt. % C18:3n6 Methyl y-inolenate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C18:3n3 Methyl palmitate 4 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Ficosatienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14-Ficosatienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14-Ficosatienoic acid methyl ester 2 wt. % C20:3n3 cis-13,16-Docosatienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 dethyl tricosanoate 2 wt. % C22:2n6 dethyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester C2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester C2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid met		•
C13:0 Methyl tridecanoate 2 wt. % C14:10 Methyl myristate 4 wt. % C14:117 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:10 Methyl stearate 4 wt. % C18:10 Methyl elaidate 2 wt. % C18:119 Methyl oleate 4 wt. % C18:1n9 Methyl linolelaidate 2 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:3n6 Methyl linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:10 Methyl dis-11-eicosenoate 2 wt. % C20:10 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl behenate 4 wt. % C22:2n6 cis-13,16-Docosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosanoate 2 wt. % C22:2n6 cis-14,14-Eicosanoate 2 wt. % C22:2n6 cis-13,16-Docosanoate 2 wt. % C22:2n6 cis-14,14-Eicosanoate 2 wt. % C22:2n6 cis-13,14-Eicosanoate 2 wt. %		•
C14:0 Methyl myristate 4 wt. % C14:1n7 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitoleate 2 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl palmitoleate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:1n9 Methyl stearate 4 wt. % C18:1n9 Methyl sleaidate 2 wt. % C18:1n9 Methyl linoleate 2 wt. % C18:1n9 Methyl linoleate 2 wt. % C18:3n6 Methyl linoleate 2 wt. % C18:3n6 Methyl linoleate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 dis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 dis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-11,14-Eicosatrienoic acid methyl ester C20:3n6 cis		•
C14:1n7 Methyl myristoleate 2 wt. % C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecanoate 2 wt. % C16:1n Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl palmitoleate 2 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecanoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl oleate 4 wt. % C18:1n9 Methyl linolealadate 2 wt. % C18:2n6 Methyl linolealadate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:1n9 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosatienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-14,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-14,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-14,14-Eicosadienoic acid methyl ester 2 wt. % C2		
C15:0 Methyl pentadecanoate 2 wt. % C15:1 Methyl cis-10-pentadecenoate 2 wt. % C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl palmitoleate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 trans Methyl cleate 4 wt. % C18:1n9 Methyl oleate 4 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n6 Methyl v-linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadirenoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:0 Methyl behenate 2 wt. % C22:0 Methyl behenate 2 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,14-Eicosadienoic acid methyl ester 2 wt. % C22:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid met	C14:1n7	• •
C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl oleate 4 wt. % C18:1n9 Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C24:0 Methyl tetracosanoate 2 wt. % C25:6n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C25:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C26:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester	C15:0	
C16:0 Methyl palmitate 6 wt. % C16:1n7 Methyl palmitoleate 2 wt. % C17:0 Methyl heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl inolealaidate 2 wt. % C18:2n6 Methyl linolealaidate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linoleate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C25:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C26:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester	C15:1	• •
C17:0 Methyl heptadecanoate 2 wt. % C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:0 Methyl stearate 4 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl oleate 4 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatirenoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n7 cis-11,14,17-Eicosatirenoic acid methyl ester 2 wt. % C20:3n8 Methyl arachidonate 2 wt. % C20:3n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:2n6 Cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,11,14-Eicosadienoic acid methyl ester	C16:0	
C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl oleate 4 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatirenoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n7 Methyl arachidonate 2 wt. % C20:3n8 Methyl arachidonate 2 wt. % C20:3n9 Methyl behenate 4 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C24:10 Methyl tetracosanoate 4 wt. % C24:10 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,1,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 Methyl arachidonate C20:0 Docosanoic acid / Behenic acid * C20:1n9 cis-13-Docosenoic acid / Behenic acid *	C16:1n7	Methyl palmitoleate 2 wt. %
C17:1 Methyl cis-10-heptadecenoate 2 wt. % C18:1n9 trans Methyl elaidate 2 wt. % C18:1n9 Methyl oleate 4 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatirenoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n7 Methyl arachidonate 2 wt. % C20:3n8 Methyl arachidonate 2 wt. % C20:3n9 Methyl behenate 4 wt. % C22:1n9 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C24:10 Methyl tetracosanoate 4 wt. % C24:10 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-3,1,14-Eicosadienoic acid methyl ester C20:3n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 Methyl arachidonate C20:0 Docosanoic acid / Behenic acid * C20:1n9 cis-13-Docosenoic acid / Behenic acid *		
C18:1n9 trans Methyl elaidate 2 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linolelaidate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,Ficosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,T-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C10:1n9 cis-11,14-Eicosadienoic acid methyl ester C20:2n6	C17:1	
C18:1n9 Methyl oleate 4 wt. % C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:3n6 Methyl y-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:1n9 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n0 Methyl behenate 4 wt. % C20:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C20:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 Methyl tetracosanoate 4 wt. % C24:0 Methyl tetracosanoate 2 wt. % C24:0 Methyl cis-15-tetracosenoate 2 wt. % C26:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:0	Methyl stearate 4 wt. %
C18:2n6t Methyl linolelaidate 2 wt. % C18:2n6 Methyl linoleate 2 wt. % C18:3n3 Methyl y-linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:1n9 trans	Methyl elaidate 2 wt. %
C18:2n6 Methyl linoleate 2 wt. % C18:3n3 Methyl y-linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C20:1n9 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:1n9	Methyl oleate 4 wt. %
C18:3n6 Methyl γ-linolenate 2 wt. % C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:2n6t	Methyl linolelaidate 2 wt. %
C18:3n3 Methyl linolenate 2 wt. % C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:3n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:10 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:3n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:2n6	Methyl linoleate 2 wt. %
C20:0 Methyl arachidate 4 wt. % C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid methyl ester C20:1n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:3n6	Methyl γ-linolenate 2 wt. %
C20:1n9 Methyl cis-11-eicosenoate 2 wt. % C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C20:3n9 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:1n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C18:3n3	Methyl linolenate 2 wt. %
C21:0 Methyl heneicosanoate 2 wt. % C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,7-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C22:1n9 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C22:2n6 Methyl tetracosanoate 4 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C20:0	Methyl arachidate 4 wt. %
C20:2n6 cis-11,14-Eicosadienoic acid methyl ester 2 wt. % C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,7-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C20:1n9	Methyl cis-11-eicosenoate 2 wt. %
C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester 2 wt. % C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C21:0	
C20:4n6 Methyl arachidonate 2 wt. % C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C20:2n6	cis-11,14-Eicosadienoic acid methyl ester 2 wt. %
C20:3n3 cis-11,14,17-Eicosatrienoic acid methyl ester 2 wt. % C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *	C20:3n6	•
C22:0 Methyl behenate 4 wt. % C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl tetracosanoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C22:1n9 Methyl cis-13-docosenoate 2 wt. % C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl teis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C20:5n3 cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester 2 wt. % C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C23:0 Methyl tricosanoate 2 wt. % C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C22:2n6 cis-13,16-Docosadienoic acid methyl ester 2 wt. % C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosadienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C24:0 Methyl tetracosanoate 4 wt. % C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C24:1n9 Methyl cis-15-tetracosenoate 2 wt. % C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C2:0 Docosanoic acid / Behenic acid * C2:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 2 wt. % C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C16:1n7 palmitoleic acid / cis-9-Hexadecenoic acid * C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C17:0 Heptadecanoic acid * C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C20:1n9 cis-11-Eicosenoic acid * C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
C20:2n6 cis-11,14-Eicosadienoic acid methyl ester C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		-
C20:3n6 cis-8,11,14-Eicosatrienoic acid methyl ester C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C20:4n6 Methyl arachidonate C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		·
C22:0 Docosanoic acid / Behenic acid * C22:1n9 cis-13-Docosenoic acid / Erucic acid *		
C22:1n9 cis-13-Docosenoic acid / Erucic acid *		•
(120)-bn3 cie-5 8 11 14 17-Eicceanentaenoic acid methyl geter	C20:5n3	cis-5,8,11,14,17-Eicosapentaenoic acid methyl ester
C22:2n6 cis-13,16-Docosadienoic acid methyl ester		
C24:1n9 cis-15-Tetracosenoic acid / Nervonic acid *		•
C22:6n3 cis-4,7,10,13,16,19-Docosahexaenoic acid *		
DMA 16:0 16:0 dimethylacetal		
DMA 18:0 18:0 dimethylacetal		-
DMA 18:1 18:1 dimethylacetal		
C18:1n7 trans trans- Vaccenic acid / 11-trans-Octadecenoic acid *		
C18:1n7 Cis cis-vaccenic acid / cis-11-Octadecenoic acid *		
C22:4n6 cis-7,10,13,16-Docosatetraenoic acid *		
C22:5n3 cis-7,10,13,16,19-Docosapentaenoic methyl ester	C22:5n3	cis-7,10,13,16,19-Docosapentaenoic methyl ester

FAME peaks were identified by comparison with the retention times of previously injected authentic standards. All fatty acid standards were obtained from Sigma-Aldrich (Merck, Germany) and are presented as supplementary material. Peak areas were quantified (EZChrom Chromatography Data System, Scientific Software Inc., San Ramon, CA, USA) and the values presented as % of total fatty acids.

Statistical analysis

Shapiro-Wilk test was performed in order to confirm the normal distribution of body weight gain (BW), tissue mass and tissue FA composition. Data are expressed as mean \pm standard deviation of the mean. One-way ANOVA followed by Tukey's HSDpost hoc test was employed to identify differences amongst individual groups. All tests were performed with SPSS Version 26 for p < 0.05 (IBM, Chicago, IL, USA).

RESULTS

SOD and FOD show substantially different fatty acid profiles

The FA profiles of the fish oil and the soybean oil used in this study are shown in Table I, alongside the FA composition of the Ctrl, FOD and SOD diets. Nearly 75% of the fish oil FA comprised EPA and DHA, featuring also nearly identical amounts of LA (0.4%) and ALA (0.3%). The fish oil contained under 8% of Σ MUFAs, with 4.5% oleic acid (OA), and the Σ SFA was under 3%. The only N3FA detected in soybean oil was ALA, with 5.3% of the total FA content. The soybean oil also contained 52.2% of LA, 10.7% of palmitic acid (PA) and 26.2% OA (Table I).

The Ctrl diet FA profile resembles the profile of the soybean oil, with 4.1% ALA, 54.9% LA, 24.6% OA and 12.5% PA (Table I). The FOD contained 0.8% ALA, 39.9% EPA, 22.1% DHA, 7.5% LA, 7% OA and 2.2% PA. The SOD contained 5.7% ALA, 51.3% LA, 25.6% OA and 11.2% PA. Whilst the FOD N6/N3 ratio was 0.15, the SOD ratio was 9.02 (Table I).

Body and tissue weight were distinctly affected in SOD and FOD

The BW gain (calculated as BW on the final day of dietary intervention minus BW on the first day of dietary intervention) of the SOD rats at the end of dietary intervention was significantly higher than the FOD rats (Table II), however no differences were observed between SOD and Ctrl groups. The liver relative weight was significantly higher in FOD, and significantly lower in SOD, as compared to Ctrl. The RET relative weight was significantly lower in FOD and bigger in SOD as compared to Ctrl. The EPI relative weight was significantly higher in SOD as compared to FOD and Ctrl. The MES relative weight was significantly higher in SOD as compared to Ctrl. No differences were detected in hypothalamus relative weight (Table II).

Table I. Fatty acid composition (% of total fatty acids) of the fish oil, soybean oil, control diet (Ctrl), fish oil-enriched diet (FOD) and soybean oil-enriched diet (SOD).

	Abbreviation	Fish oil	Soybean oil	Ctrl	FOD	SOD
c16:0	PA	0.5	10.7	12.3	2.2	11.2
c18:0	SA	2.2	2.8	2.4	2.2	3
ΣSFA		2.8	13.7	14.8	4.5	14.3
c16:1n-7	POA	0.2	0.1	0	0.2	0.1
c18:1n-9	OA	4.5	26.2	24.6	7	25.6
c18:1n-7	VA	1.5	1.5	1.1	1.3	1.5
c20:1		1.4	0.2	0.2	1.2	0.2
c24:1		0.3			0.3	
ΣMUFA		7.8	28	25.9	10	27.4
c18:2n-6	LA	0.4	52.2	54.9	7.5	51.3
c18:3n-6	GLA	0.1	0	0		0.1
c20:3n-6	DHGLA	0.3			0.2	
c20:4n-6	AA	2.1			1.8	
c22:4n-6	N6-DTA	0.2			0.1	
c22:5n-6	N6-DPA	0.5			0.5	
ΣN6PUFA		3.5	52.2	54.9	10.2	51.4
c18:3n-3	ALA	0.3	5.3	4.1	0.8	5.7
c20:5n-3	EPA	47.3			39.9	
c22:5n-3	N3-DPA	4.9			4.5	
c22:6n-3	DHA	25.6			22.1	
ΣN3PUFA		78.1	5.3	4.1	67.2	5.7
N6/N3		0.04	9.85	13.39	0.15	9.02

SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitic acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; WA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid

Table II. Body weight (BW) gain (g) (BW at the end of dietary intervention minus first study day), relative tissue weight (g tissue / 100 g BW) of retroperitoneal (RET), epidydimal (EPI) and mesenteric (MES) adipose tissue, liver, and hypothalamus.

	Ctrl	-		FOD				SOD			
	Mean		SD	Mean		SD		Mean		SD	
BW gain (g)	179.8	±	27.2	153.9	±	35.2		216.5	±	30.8	*
Liver	3.30	±	0.22	4.09	±	0.12	#	3.14	±	0.20	*
RET	1.11	±	0.14	0.76	±	0.12	#	1.93	±	0.26	#*
EPI	1.29	±	0.16	1.46	±	0.30		1.88	±	0.23	#*
MES	1.06	±	0.18	1.49	±	0.17		1.70	±	0.40	#
Hypothalamus	0.011	±	0.001	0.011	±	0.001		0.011	±	0.000	

Data presented as means \pm SD. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

Liver fatty acid profile shows increased N6 in SOD rats

The liver FA profile is presented in Table III. The SOD group showed significantly lower amounts of stearic (SA), and lower \sum SFA, in relation to FOD. OA was higher, vaccenic acid (VA) was lower, and the \sum MUFA content was higher in SOD as compared to FOD. N6-DPA was the only N6 FA not significantly higher in SOD as compared to FOD; all the other N6FAs were significantly higher in SOD. Except for ALA, N3 FAs were significantly decreased in SOD as compared to FOD. The N6/N3 ratio was significantly higher in SOD as compared to FOD. In comparison to Ctrl, the SOD rats showed overall decreased SFA, increased MUFA and N6PUFA, and unchanged N3PUFA (Table III).

Table III. Fatty acid composition of liver total lipid extract obtained from male Wistar rats fed a standard rodent chow (Ctrl) (2.7kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1 kcal/g) for 8 weeks.

		Ctrl			FOD				SOD			
	Abbreviation	М		SD	M		SD		М		SD	
C16:0	PA	17.61	±	1.08	12.87	±	1.16	#	14.22	±	0.61	#
C18:0	SA	14.66	±	0.98	16.71	±	0.97		10.95	±	2.47	#*
ΣSFA		33.0	±	1.1	30.0	±	0.6	#	25.6	±	2.4	#*
C16:1n-7	POA	0.74	±	0.35	0.40	±	0.08		0.18	±	0.02	#
C18:1n-9	OA	7.34	±	0.56	8.45	±	1.12		13.71	±	1.88	#*
C18:1n-7	VA	3.27	±	0.38	2.27	±	0.23	#	1.65	±	0.07	#*
ΣMUFA		11.7	±	1.0	11.7	±	1.0		15.8	±	1.8	#*
C18:2n-6	LA	18.04	±	1.66	10.44	±	0.83	#	28.32	±	3.22	#*
C18:3n-6	GLA	0.26	±	0.01	0.05	±	0.02	#	0.61	±	0.08	#*
C20:3n-6	DHGLA	0.55	±	0.04	0.57	±	0.05		0.90	±	0.14	#*
C20:4n-6	AA	25.07	±	0.88	12.35	±	1.40	#	17.19	±	2.90	#*
C22:4n-6	N6-DTA	0.86	±	0.06	0.03	±	0.01	#	1.33	±	0.34	#*
C22:5n-6	N6-DPA	0.23	±	0.11	0.15	±	0.02		0.27	±	0.16	
ΣN6PUFA		45.0	H	1.6	23.6	Ħ	0.7	#	48.6	H	1.2	#*
C18:3n-3	ALA	0.35	±	0.07	0.48	±	0.12		0.59	±	0.52	
C20:5n-3	EPA	0.31	±	0.05	13.79	±	0.72	#	0.41	±	0.11	*
C22:5n-3	N3-DPA	1.48	±	0.25	3.63	±	0.49	#	1.09	±	0.16	*
C22:6n-3	DHA	4.98	±	1.09	12.31	±	1.05	#	5.19	±	0.76	*
ΣN3PUFA		7.10	±	0.83	30.21	±	1.13	#	7.29	±	0.79	*
N6/N3		6.4	±	8.0	8.0	±	0.0	#	6.8	±	0.9	*

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitic acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; ALA: Alnoleic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosatetraenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

Serum fatty acid profile shows improved N3 in SOD

The serum FA profile is presented in Table IV. There were no differences in SFA content between SOD and FOD. Palmitoleic acid (POA) was significantly decreased in SOD, and so was the \sum MUFA content. Except for N6-DPA, all N6 FAs were significantly higher in SOD as compared to FOD. ALA was significantly higher in SOD as compared to FOD, but the other N3 FAs were higher in FOD. Same as what was observed in liver, the N6/N3 ratio was significantly higher in SOD as compared to FOD. Interestingly, the DHA content was significantly higher in SOD as compared to Ctrl (Table IV).

Table IV. Fatty acid composition of serum total lipid extract obtained from male Wistar rats fed a standard rodent chow (Ctrl) (2.7 kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1 kcal/g) for 8 weeks.

		Ctrl			FOD				SOD			
	Abbreviation	М		SD	M		SD		M		SD	
C16:0	PA	20.35	±	0.91	20.18	±	2.70		17.49	±	0.62	#
C18:0	SA	11.99	±	0.58	15.94	±	2.03	#	15.42	±	1.28	#
ΣSFA		32.9	±	1.0	36.7	±	4.7		33.3	±	1.6	
C16:1n-7	POA	0.81	±	0.26	0.53	±	0.06	#	0.25	±	0.10	#*
C18:1n-9	OA	9.53	±	0.98	8.58	±	0.21		7.14	±	1.18	#
C18:1n-7	VA	2.01	±	0.30	1.35	±	0.08	#	1.09	±	0.10	#
ΣMUFA		12.6	±	1.1	11.2	±	0.3		8.8	±	1.4	#*
C18:2n-6	LA	20.52	±	0.82	6.38	±	1.26	#	16.90	±	0.96	#*
C18:3n-6	GLA	0.23	±	0.03	0.06	±	0.02	#	0.18	±	0.10	*
C20:3n-6	DHGLA	0.35	±	0.08	0.25	±	0.05		0.38	±	0.07	*
C20:4n-6	AA	26.11	±	0.90	10.90	±	0.86	#	33.07	±	0.69	#*
C22:4n-6	N6-DTA	0.57	±	0.13	0.06	±	0.05	#	0.38	±	0.12	#*
C22:5n-6	N6-DPA	0.13	±	0.07	0.16	±	0.04		0.14	±	0.07	
ΣN6PUFA		47.9	±	1.5	17.8	±	2.1	#	51.1	±	0.6	#*
C18:3n-3	ALA	0.44	±	0.05	0.25	H	0.03	#	0.36	±	0.06	#*
C20:5n-3	EPA	0.45	±	0.11	21.04	±	3.65	#	0.23	±	0.11	*
C22:5n-3	N3-DPA	0.92	±	0.11	1.81	±	0.24	#	0.51	±	0.09	#*
C22:6n-3	DHA	2.52	±	0.50	8.44	±	1.08	#	3.86	±	0.44	#*
ΣN3PUFA		4.35	±	0.40	31.54	±	4.94	#	4.97	±	0.52	*
N6/N3		11.1	±	1.1	0.6	±	0.1	#	10.4	±	1.2	*

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitic acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

Hypothalamus fatty acid profile shows increased DHA in SOD compared to Ctrl

The hypothalamus FA profile is presented in Table V. No significant differences in SFA content were found between SOD and FOD. POA and OA were significantly lower in SOD as compared to FOD, contributing to lower \sum MUFA content. The amounts of the less unsaturated and shorter N6 FAsLA, gamma-linolenic (GLA) and dihomo-gamma-linolenic (DHGLA) acids were the same between SOD and FOD, but the longer and more unsaturated AA, N6 docosatetraenoic (N6-DTA) and N6-DPA were significantly higher in SOD, which contributed to higher \sum N6PUFA content. The amount of EPA was lower in SOD, but no other statistically significant differences were found in N3 fatty acids between SOD and FOD. The SOD group was the only to show a hypothalamic N6/N3 ratio of 1.0, which was statistically lower than Ctrl and statistically higher than FOD. Same as in serum, the DHA content was significantly higher in SOD as compared to Ctrl (Table V), a result that was not found for SOD rats in their other peripheral tissues.

Table V. Fatty acid composition of hypothalamus total lipid extract obtained from male Wistar rats fed a standard rodent chow (Ctrl) (2.7 kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1 kcal/g) for 8 weeks.

		Ctrl				FOD					SOD			
	Abbreviation	M		SD		М		SD			M		SD	
C16:0	PA		_				_					_		
0.0.0		19.87	±	0.78		18.85	±	1.11			18.44	±	0.89	
C18:0	SA	18.12	±	0.44		17.95	±	0.24			17.89	±	0.54	
ΣSFA		38.4	±	1.0		37.2	±	1.1			36.8	±	0.6	
C16:1n-7	POA	0.48	±	0.05		0.50	±	0.04			0.41	±	0.02	*
C18:1n-9	OA	20.90	±	0.50		21.72	±	0.56			20.19	±	0.44	*
C18:1n-7	VA	3.95	±	0.28		3.44	±	0.28	#		3.56	±	0.07	
ΣMUFA		26.5	±	0.8		27.5	±	0.8			25.3	±	0.4	*
C18:2n-6	LA	1.35	±	0.95		0.40	±	0.07	#		0.90	±	0.14	
C18:3n-6	GLA	0.04	±	0.01		0.05	±	0.01			0.05	±	0.05	
C20:3n-6	DHGLA	0.22	±	0.02		0.21	±	0.04			0.23	±	0.06	
C20:4n-6	AA	10.68	±	0.97		9.01	±	0.30	#		11.28	±	0.17	*
C22:4n-6	N6-DTA	3.43	±	0.16		2.42	±	0.10	#		3.73	±	0.18	#*
C22:5n-6	N6-DPA	0.39	±	0.02		0.14	±	0.02	#		0.52	±	0.12	*
ΣN6PUFA		16.1	±	0.3		12.2	±	0.4	#		16.7	±	0.3	#*
C18:3n-3	ALA	0.05	±	0.04		0.03	±	0.02			0.06	±	0.03	
C20:5n-3	EPA	0.07	±	0.03		0.49	±	0.09	#		0.15	±	0.02	*
C22:5n-3	N3-DPA	1.08	±	0.70		1.07	±	0.08			0.92	±	0.16	
C22:6n-3	DHA	12.97	±	1.74		17.18	±	1.46	#		16.03	±	0.84	#
ΣN3PUFA	" '	14.16	±	2.00		18.76	±	1.53	#		17.15	±	0.81	#
		7 11 10	Ė	2.00		10.70	Ė	1.00	l"			-	3.01	<u> </u>
N6/N3		12	+	0.2	-	0.7	+	0.1	#	-	1.0	+	0.0	#*
N6/N3		1.2	±	0.2		0.7	±	0.1	#		1.0	±	0.0	#'

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitto acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

Epidydimal white adipose tissue fatty acid profile is negatively affected in SOD

The EPIFA profile is presented in Table VI. The amounts of PA and SA were slightly lower in SOD as compared to FOD, but their individual differences did not reach statistical significance. When added together however, their lower concentration contributed to significantly lower Σ SFA content in SOD as compared to FOD. The SOD group showed significantly lower amounts of POA, but significantly higher amounts of OA, which led to a significantly higher Σ MUFA content in SOD compared to FOD. The EPI N6 FA profile appears to be more complex than in the previously described tissues. LA and N6-DTA were significantly higher in SOD as compared to FOD. Whilst GLA and DHGLA were similar, AA and N6-DPA were significantly lower in SOD. The Σ N6PUFA was significantly higher in SOD as compared to FOD, leading to lower Σ N3PUFA content in SOD. The N6/N3 ratio was nearly twenty times higher in SOD as compared to FOD (Table VI).

Table VI. Fatty acid composition of epidydimal adipose tissue total lipid extract obtained from male Wistar rats fed a standard rodent chow (Ctrl) (2.7 kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (FOD) (4.1 kcal/g) for 8 weeks

		Ctrl			FOD				SOD			
	Abbreviation	M		SD	M		SD		M		SD	
C16:0	PA	20.35		0.70	17.51		1.75	#	15.63	_	0.96	#
	SA		±			±		#		±	0.00	#
C18:0	5A	2.74	±	0.32	3.22	±	0.42		3.12	±	0.30	114
ΣSFA		23.9	±	0.8	21.9	±	1.7		19.3	±	1.2	#*
C16:1n-7	POA	2.78	±	1.12	3.71	±	1.02		1.34	±	0.36	*
C18:1n-9	OA	24.24	±	0.45	16.99	±	0.97	#	26.01	±	0.39	#*
C18:1n-7	VA	2.66	±	0.27	2.14	±	0.15	#	1.88	±	0.14	#
ΣMUFA		29.9	±	1.5	23.3	±	1.7	#	29.4	±	0.5	*
C18:2n-6	LA	39.06	±	1.52	17.98	±	1.52	#	44.38	±	1.03	#*
C18:3n-6	GLA	0.11	±	0.01	0.07	±	0.02	#	0.08	±	0.01	#
C20:3n-6	DHGLA	0.20	±	0.04	0.22	±	0.04		0.20	±	0.03	
C20:4n-6	AA	1.61	±	0.27	1.67	±	0.18		1.07	±	0.23	#*
C22:4n-6	N6-DTA	0.40	±	0.08	0.11	±	0.04	#	0.23	±	0.06	#*
C22:5n-6	N6-DPA	0.09	±	0.03	0.18	±	0.05	#	0.06	±	0.03	*
ΣN6PUFA		41.5	±	1.5	20.2	±	1.4	#	46.0	±	1.1	#*
C18:3n-3	ALA	2.43	±	0.14	1.31	±	0.08	#	3.23	±	0.20	#*
C20:5n-3	EPA	0.09	±	0.03	16.16	±	1.64	#	0.10	±	0.03	*
C22:5n-3	N3-DPA	0.32	±	0.09	3.31	±	0.47	#	0.23	±	0.08	*
C22:6n-3	DHA	0.33	±	0.07	10.21	±	1.58	#	0.29	±	0.10	*
ΣN3PUFA		3.18	±	0.24	30.98	±	3.40	#	3.84	±	0.26	*
N6/N3		13.1	±	0.8	0.7	±	0.1	#	12.0	±	0.8	#*

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitto acid; SA: Stearic acid; POA: Palmittoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs. Ctrl. * p< 0.05 vs. FOD.

Retroperitoneal white adipose tissue fatty acid profile is negatively affected in SOD

The RET FA profile is presented in Table VII. The amounts of PA and SA were significantly lower in SOD as compared to FOD, contributing to significantly lower Σ SFA content. The SOD group showed significantly lower amounts of POA and VA, but significantly higher amounts of OA, which led to a significantly higher Σ MUFA content in SOD compared to FOD. The RET N6 profile was nearly identical to the one found in EPI: LA was significantly higher in SOD as compared to FOD. N6-DTA was also higher, but the difference between SOD and FOD did not reach statistical significance. GLA and DHGLA were similar, whilst AA and N6-DPA acids were significantly lower, in SOD as compared to FOD. The Σ N6PUFA was significantly higher in SOD as compared to FOD. The RET N3 profile was identical to the one found in EPI: ALA was significantly higher, whilst the other N3 FAs and the Σ N3PUFA content were lower, in SOD as compared to FOD. Same as for EPI, the RET N6/N3 ratio was nearly twenty times higher in SOD as compared to FOD (Table VII).

Table VII. Fatty acid composition of retroperitoneal adipose tissue total lipid extract obtained from male Wistar rats fed a standard rodent chow (Ctrl) (2.7 kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1 kcal/g) for 8 weeks.

		Ctrl				FOD					SOD			
	Abbreviation	M		SD		M		SD			M		SD	
C16:0	PA	20.76	±	0.52	Г	20.16	±	1.19		Г	15.49	±	1.46	#*
C18:0	SA	2.97	±	0.09		4.24	±	0.32	#		3.25	±	0.18	*
ΣSFA		24.6	±	0.5		25.7	±	1.4			19.2	±	1.7	#*
C16:1n-7	POA	2.06	±	0.18		2.37	±	0.57			0.86	±	0.36	#*
C18:1n-9	OA	24.96	±	0.67		19.66	±	1.11	#		26.55	±	0.71	#*
C18:1n-7	VA	2.72	±	0.33		2.51	±	0.21			1.84	±	0.04	#*
ΣMUFA		30.0	±	0.9		25.3	±	0.9	#		29.5	±	0.4	*
C18:2n-6	LA	39.70	±	0.99		18.10	±	1.63	#		45.42	±	2.13	#*
C18:3n-6	GLA	0.08	±	0.02		0.05	±	0.02	#		0.07	±	0.01	
C20:3n-6	DHGLA	0.15	±	0.03		0.22	±	0.03	#		0.18	±	0.06	
C20:4n-6	AA	0.98	±	0.19		1.29	±	0.13	#		0.78	±	0.20	*
C22:4n-6	N6-DTA	0.27	±	0.07		0.14	±	0.05	#		0.21	±	0.05	
C22:5n-6	N6-DPA	0.06	±	0.01		0.26	±	0.06	#		0.03	±	0.02	*
ΣN6PUFA		41.3	±	1.0		20.1	±	1.7	#		46.7	±	1.9	#*
C18:3n-3	ALA	2.27	±	0.18		1.04	±	0.08	#		2.95	±	0.18	#*
C20:5n-3	EPA	0.06	±	0.01		10.51	±	2.71	#		0.08	±	0.01	*
C22:5n-3	N3-DPA	0.21	±	0.04		3.66	±	0.40	#		0.16	±	0.02	#*
C22:6n-3	DHA	0.16	±	0.04		10.56	±	0.91	#		0.18	±	0.06	*
ΣN3PUFA		2.70	±	0.22		25.78	±	1.93	#		3.37	±	0.22	*
N6/N3		15.3	±	1.1		0.8	±	0.1	#		13.9	±	1.5	*

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitic acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

Mesenteric white adipose tissue fatty acid profile is negatively affected in SOD

The MES FA profile is presented in Table VIII. The amount of SA was significantly lower in SOD as compared to FOD, but as opposed to EPI and RET, the Σ SFA content in MES was similar between SOD and FOD. The MUFA, N6 and N3 PUFA profile observed in MES was identical to the one observed in RET.

Table VIII. Fatty acid composition of mesenteric adipose tissue total lipid extract obtained from male Wistar rats fed a
standard rodent chow (Ctrl) (2.7 kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1 kcal/g) for 8 weeks.

		Ctrl			FO				so			
	Abbreviation	M		SD	М		SD		M		SD	
C16:0	PA	19.27	±	0.88	13.49	±	1.07	#	14.22	±	0.80	#
C18:0	SA	3.22	±	0.21	4.49	±	0.25	#	3.53	±	0.24	*
ΣSFA		23.2	±	1.0	18.9	±	1.2	#	18.1	±	0.9	#
C16:1n-7	POA	1.27	±	0.27	1.24	±	0.35		0.53	±	0.19	#*
C18:1n-9	OA	25.92	±	0.68	16.83	±	0.38	#	27.82	±	0.39	#*
C18:1n-7	VA	2.72	±	0.22	2.77	±	0.08		1.92	±	0.07	#*
ΣMUFA		30.1	H	1.0	21.4	±	0.6	#	30.5	±	0.4	*
C18:2n-6	LA	41.50	±	1.36	16.98	±	1.19	#	46.20	±	1.19	#*
C18:3n-6	GLA	0.07	±	0.01	0.08	±	0.03		0.05	±	0.01	
C20:3n-6	DHGLA	0.11	±	0.02	0.11	±	0.13		0.12	±	0.03	
C20:4n-6	AA	0.80	±	0.07	1.83	±	0.10	#	0.57	±	0.10	#*
C22:4n-6	N6-DTA	0.26	±	0.04	0.12	±	0.01	#	0.14	±	0.05	#
C22:5n-6	N6-DPA	0.05	±	0.02	0.27	±	0.03	#	0.03	±	0.01	*
ΣN6PUFA		42.8	±	1.4	19.4	±	1.1	#	47.1	±	1.0	#*
C18:3n-3	ALA	1.98	±	0.24	1.12	±	0.06	#	2.61	±	0.21	#*
C20:5n-3	EPA	0.05	±	0.01	15.92	±	0.82	#	0.03	±	0.01	*
C22:5n-3	N3-DPA	0.19	±	0.04	4.29	±	0.18	#	0.11	±	0.03	*
C22:6n-3	DHA	0.15	±	0.02	13.23	±	1.35	#	0.11	±	0.04	*
ΣN3PUFA		2.37	±	0.23	34.56	±	1.96	#	2.86	±	0.21	*
N6/N3		18.2	±	1.3	0.6	±	0.0	#	16.5	±	1.2	*

Data presented as mean ± SD of the % of total fatty acids. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; PA: palmitic acid; SA: Stearic acid; POA: Palmitoleic acid; OA: oleic acid; VA: cis-vaccenic acid; LA: Linoleic acid; GLA: gamma-linolenic acid; DHGLA: dihomo-gamma-linolenic acid; AA: Arachidonic acid; N6-DTA: N6-docosatetraenoic acid; N6-DPA: N6-docosapentaenoic acid; ALA: Alpha-linolenic acid; EPA: Eicosapentaenoic acid; N3-DPA: N3-docosapentaenoic acid; DHA: Docosahexaenoic acid. # p< 0.05 vs Ctrl. * p< 0.05 vs. FOD.

$LA/AA\ and\ ALA/DHA\ ratios\ are\ unbalanced\ in\ SOD\ compared\ to\ Ctrl\ and\ FOD$

In the liver, the LA/AA ratio was significantly higher in SOD as compared to both FOD and Ctrl. Although not statistically significant, the ALA/DHA ratio was three times higher in SOD as compared to FOD, and nearly doubled in SOD as compared to Ctrl. In serum, the ratio LA/AA was similar between SOD and FOD, and both were significantly lower than Ctrl. The ALA/DHA was significantly lower in FOD as compared to SOD, which was significantly lower as compared to Ctrl. There were no statistically significant differences in hypothalamic LA/AA or ALA/DHA ratios, although it appears the ratios reduce from Ctrl to SOD and from SOD to FOD.

In EPI, the LA/AA ratio was significantly higher in SOD as compared to Ctrl, which in turn was significantly higher as compared to FOD. The ALA/DHA ratio was significantly higher in SOD as compared to FOD, but SOD was not significantly higher than Ctrl. In RET, both LA/AA and ALA/DHA ratios were significantly higher in SOD as compared to FOD, but the SOD ratios were not significantly higher than Ctrl. In MES, both LA/AA and ALA/DHA ratios were significantly higher in SOD as compared to Ctrl, which were significantly higher as compared to FOD.

DISCUSSION

Obesity and other metabolic conditions characterized by mild chronic inflammatory backgrounds, including metabolic syndrome and type 2 diabetes⁽⁴¹⁾, cardiovascular disease⁽⁴²⁾, dyslipidaemia⁽⁴³⁾ and dementia⁽⁴⁴⁾ are major Public Health issues. Combined, their mortality rates constitute by far the most important cause of death worldwide^(45,46).

High fat diets are long known for their role in the development of obesity⁽⁴⁷⁾ and inflammation⁽⁴⁸⁾. Not only the amount of fat but also the imbalanced proportion of N6 to N3FAs are well known to exacerbate chronic conditions^(49,50).

A typical westernised diet features abundance of red meat and derivatives⁽⁵¹⁾, which are often cooked with plant oils. The five most consumed plant oils in the Western world are palm oil, sunflower oil, corn oil, rapeseed oil and soybean oil^(12,15). The first four aforementioned oils are important sources of not only OA but also LA^(16,17,52). However, amongst the five oils mentioned above, soybean oil is the one with the highest ALA content. Whilst Alves found a concentration of 2.7% ALA in soybean oil(17), Kim found 7.8%⁽¹⁶⁾,and in our study the ALA concentration found was 5.3%. Although it is worth noting the different protocols employed across the three studies, the overall ALA concentrations agree with the range found in other soybean oil FA studies.

Seawaterfish is the most important source of long chain N3PUFAs, particularly EPA and DHA, but marine mammals – a food source for some cultures such as the Inuit – also show higher N3 content as compared to humans⁽⁵³⁾. There is currently no government-set specific recommendation for the N6/N3 ratio⁽⁵⁴⁾, but there is a suggestion that it would be appropriate to maintain it below 5/1⁽⁵⁵⁾. It has been described that Western populations show a N6/N3ratio of 15 to 16/1⁽³⁰⁾, reaching levels as high as 20/1⁽³¹⁾.

A simplistic approach to resolve the high N6/N3 ratio would be to increase fish intake. However, two paramount issues are associated with increasing fish consumption. Firstly, fish is more expensive than meat⁽²⁵⁾, a factor of significant importance when considering food choices for low-income families. Secondly, due to the total global demand, fish consumption is at its historical high levels, leading to a catastrophic impact upon marine environment. Fishing is no longer a commercially sustainable activity(27,28,29). Another simplistic approach to resolve the high N6/N3 ratio would be to decrease N6 intake, which works only up to a certain extent, as it does not excuse the essentiality of N3 FAs. An urgent alternative for fish-derived N3 FAs is required to provide the nutritional demands for humans. Some plant oils are under intense scrutiny due to their important ALA content, for example walnut oil (56). Several studies have investigated the effects of walnut oil intake upon the secretory function of the adipose tissue (57), biomarkers of cardiovascular function⁽⁵⁸⁾, type 2 diabetes⁽³⁷⁾ and obesity⁽⁵⁹⁾, amongst others. In the present study, we chose to investigate the effects of a soybean oil-enriched diet upon tissue fatty acid composition, comparing the results to the well-known effects of diets enriched with fish oil. Soybean oil is significantly more affordable than walnut oil.

In the present study, rats were kept on one of the three diets for 8 weeks ad libitum. The body weight gain accrued along the period of dietary intervention was statistically higher in SOD as compared to FOD, while Ctrl showed a body weight gain that was intermediary and statistically similar between both SOD and FOD (Table II). The RET and EPI relative weight (g/100 g BW) was significantly higher in SOD as compared to Ctrl and FOD, whilst MES was significantly higher in SOD as compared to Ctrl only. The liver relative weight was significantly lower in SOD as compared to FOD, and similar to Ctrl (Table II). We have not measured carcass total lipid content, but the combined findings of higher adipose tissue relative weight associated with lower liver relative weight in SOD rats suggest that SOD are more obese than Ctrl and FOD. This suggestion is further corroborated by the significant findings of higher body weight in SOD when compared to FOD. Furthermore, although not statistically different, SOD group showed an increment of 17% in body weight gain compared to Ctrl group, which suggests that a longer experimentation period would have made the SOD rats also significantly more obese than Ctrl.

The SOD liver fatty acid profile is dramatically different from FOD (Table III). Σ SFA and Σ N3PUFA were significantly lower in SOD, whilst Σ MUFA and Σ N6PUFA were significantly higher. The N6/N3 ratio was 8.5 times higher in SOD as compared to FOD. Relevant differences were also found between SOD and Ctrl: whilst Σ SFA was significantly decreased, Σ MUFA and Σ N6PUFA were significantly increased, with no changes in Σ N3PUFA. Interestingly however, the N6/N3 ratio was nearly identical between SOD and Ctrl (Table III).

The SOD serum FA profile showed important differences as compared to FOD. Furthermore, the serum results (Table IV) are surprisingly different from the liver results (Table III). Serum Σ SFA is similar between SOD and FOD, and in the opposite direction of the liver profile, Σ MUFA is lower in SOD as compared to FOD. Σ N6PUFA was significantly higher, and Σ N3PUFA significantly lower, in SOD as compared to FOD. The N6/N3 ratio was17 times higher in SO as compared to FO (Table IV).

An unexpected finding in serum SO was its N3 FA profile compared to Ctrl. Whilst ALA and N6-DPA were significantly lower, DHA was significantly higher, in SOD as compared to Ctrl (Table IV). Such finds suggest enhanced uptake of ALA by SOD peripheral tissues followed by bioconversion to its longer forms and exportation, hence the higher ALA available in their diet, but combined with lower ALA and higher DHA in serum (Table IV).

The hypothalamus was also subjected to FA changes following the dietary intervention (Table V). Whilst Σ SFA and Σ N3PUFA was similar between SOD and FOD, Σ MUFA was lower and Σ N6PUFA was higher in SOD as compared to FOD. The N6/N3 ratio was significantly higher in SOD as compared to FOD. Important differences were found between SOD and Ctrl. Σ N6PUFA and Σ N3PUFA were significantly higher in SOD. The Σ N3PUFA differences are attributed mainly to significantly increased DHA in SOD. Despite not reaching statistical

significance, the EPA level in SOD was doubled in relation to Ctrl. The hypothalamic N6/N3 ratio was significantly lower in SOD as compared to Ctrl.

It has been suggested that the overall N6/N3 ratio in the healthy human brain is close to 1/1(31 and others). Interestingly, the SOD group was the only to show a hypothalamic N6/N3 ratio of 1.0 exactly (Table V). However, a direct comparison cannot be made due to obvious species differences. Some small differences can be expected even between rodents. For example, Carrié and colleagues found in 4-months old mice fed a 6% fatcontent diet, whose FA profile contained 3.6% ALA, that the hypothalamic AA content was $8.8\% \pm 0.2$ and the DHA was $15.8\% \pm 0.6^{(60)}$, compared to our findings of AA at $10.7\% \pm 0.9$ and DHA at $12.9\% \pm 1.74$.

The FA composition of EPI (Table VI), RET (Table VII) and MES (Table VIII) showed a similar pattern following the dietary intervention across all three groups. When comparing SOD versus FOD, SOD Σ SFA was significantly lower in EPI and RET. Σ MUFA and Σ N6PUFA were higher, and Σ N3PUFA was lower, in SOD EPI, RET and MES. The N6/N3 ratio was also significantly higher in SOD as compared to FOD. When comparing SOD versus Ctrl, the results follow identical patterns across the three tissues: lower Σ SFA, higher Σ N6PUFA, and unchanged Σ MUFA and Σ N3PUFA. The N6/N3 ratio was lower in SOD as compared to Ctrl, but the only tissue in which this difference reached statistical significance was EPI.

Overall, the soybean oil diet generally decreased SFA and increased N6PUFAs in liver and white adipose tissues, as compared to Ctrl, a result that can only be expected from a diet with high N6PUFA content. However, a small amount of ALA present in soybean oil was apparently enough to increase the amount of DHA in serum and hypothalamus without reducing its concentration in liver and white adipose tissues. Such hypothesis is corroborated by our N6 findings: in comparison to Ctrl, the SOD liver and adipose tissues showed increased amounts of LA, the precursor of AA; however, the AA content in those tissues was decreased. In the opposite direction, we found lower LA and higher AA in SOD serum, as compared to Ctrl. We speculate that peripheral tissues such as the liver and adipose tissue uptake LA and ALA, elongate and desaturate them to their products AA and DHA, which are subsequently exported via blood to the brain.

It is widely accepted that the conversion of ALA to DHA in humans is less than 1%⁽⁶¹⁾. Lin and colleagues⁽⁶²⁾ demonstrated in infants that only a very small amount of administered ALA was effectively converted to DHA. Furthermore, a systematic review published in 2014 showed that the supplementation with ALA-rich nuts and seeds was not sufficient to promote significant differences in DHA content⁽⁶³⁾. On the other hand, however, it has been shown in experimental conditions that cyclooxygenases 1 and 2 reach much more slowly towards N3 as compared to N6 FAs, and the subsequent cascade of intracellular events is relatively less intense in the presence of abundant N3, as compared to abundant N6⁽⁶⁴⁾. The latter findings could further explain why we have found higher levels of DHA in SOD serum and hypothalamus as compared to Ctrl, whilst

DHA remained unchanged in liver and white adipose tissue.

In order to further explore our results, we compared and contrasted the LA/AA and ALA/DHA ratios in the six tissues analysed. A more direct comparison would be to investigate the ALA/EPA ratio instead of DHA, as the enzymes that elongate and desaturate LA to AA and ALA to EPA do not discriminate between substrates⁽⁶⁵⁾. However, as AA and DHA are the two most abundant N6 and N3 FAs in the hypothalamus of rats^(11,66) and in the human brain⁽¹⁰⁾, the ALA/DHA ratio, rather than ALA/EPA, would provide a more valuable insight.

The SOD liver, EPI, RET and MES showed increased LA/AA and ALA/DHA ratio in comparison to FOD and Ctrl in all instances, reaching statistically significant increases in eleven out of sixteen possible instances (Table IX). No differences were found in hypothalamic LA/AA and ALA/DHA ratios across the three groups. However, serum LA/AA and ALA/DHA were significantly lower in SOD as compared to Ctrl, whilst the serum ALA/DHA was higher in SOD as compared to FOD.

We have not measured elongase and desaturase activity in our study; however, as a higher ratio denotes proportionally more substrate than product, we speculate two non-self-excluding hypotheses: firstly, in the SOD group the conversion of shorter and less unsaturated fatty acids onto their longer and more unsaturated products took place peripherally in a less effective manner as compared to FOD and Ctrl, as evidenced by the ratio findings in liver and adipose tissue. Our second hypothesis is that the elongation / desaturation processes in SOD are as effective as in FOD and Ctrl, but in SOD the products are exported from peripheral tissues for preferential uptake by the brain. If any of our two hypotheses is correct, it further solidifies the evidence that despite providing sufficient amounts of essential fatty acids to the brain, a soybean oil-based diet is a deficient diet. In the longer term, such diet will only exacerbate chronic conditions with a mild pro-inflammatory background. Biomagnification of essential fatty acids has been well documented across the placenta in humans, aiming at protecting the foetus (67,68,69), and it is reasonable to suggest that biomagnification continues postpartum, aiming at protecting the brain.

In conclusion, the present study showed that the intake of a high fat diet enriched with soybean oil for 8 weeks increasedN3 FA content in the hypothalamus of rats, a result mainly attributed to the ALA content of soybean oil. However, such apparently promising finding was followed by increased markers of obesity, associated with profound disturbances in peripheral tissue FA profile. Future studies are essential to investigate the impact of nutrient-deficient diets on overall metabolism, but similarly importantly, there is a pressing need for the identification of affordable and sustainable food sources.

Table IX. Ratios of LA/AA and ALA/DHA in liver, serum, hypothalamus, epidydimal, retroperitoneal and mesenteric white adipose tissues of male Wistar rats fed a standard rodent chow (Ctrl) (2.7kcal/g), or a diet enriched with fish oil (FOD) or soybean oil (SOD) (4.1kcal/g) for 8 weeks.

	Ctrl			FOD				SOD			
Liver	M		SD	М		SD		M		SD	
LA/AA	0.72	±	0.07	0.86	±	0.16		1.71	±	0.49	#*
ALA/DHA	0.07	±	0.03	0.04	±	0.01		0.12	±	0.11	
Serum	М		SD	М		SD		М		SD	
LA/AA	0.79	±	0.03	0.58	±	0.08	#	0.51	±	0.04	#
ALA/DHA	0.18	±	0.04	0.03	±	0.00	#	0.10	±	0.02	#*
Hypothalamus	M		SD	М		SD		M		SD	
LA/AA	0.13	±	0.11	0.04	±	0.01		0.08	±	0.01	
ALA/DHA	0.004	±	0.004	0.001	±	0.001		0.004	H	0.002	
Epidydimal	М		SD	М		SD		М		SD	
LA/AA	24.9	±	4.3	10.9	±	2.0	#	43.2	H	9.1	#*
ALA/DHA	7.49	±	1.54	0.13	±	0.03	#	12.56	±	5.38	*
Retroperitoneal	М		SD	М		SD		М		SD	
LA/AA	41.5	±	7.4	14.1	±	2.3	#	62.7	±	20.5	*
ALA/DHA	14.90	±	4.62	0.10	±	0.01	#	17.84	±	4.87	*
Mesenteric	М		SD	М		SD		М		SD	
LA/AA	52.4	±	4.6	9.3	±	1.0	#	83.5	±	17.0	#*
ALA/DHA	13.71	±	3.18	0.09	±	0.01	#	25.48	±	10.03	#*

Data presented as means \pm SD. N=5 for each group. FOD: fish oil-enriched diet; SOD: soybean oil-enriched diet; LA/AA: % of linoleic acid over % of arachidonic acid; ALA/DHA: % of alpha-linolenic acid over % of docosahexaenoic acid. # p< 0.05 vs. Ctrl. * p< 0.05 vs. FOD.

Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil): Grant 2007/05360-4. Conselho Nacional de Desenvolvimento Científico e Tecnológico, Ministry of Science and Technology (CNPq, Brazil): Grants 309405/2013-0, 453924/2014-0 and 309505/2017-8. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil): Grant: Finance Code 001. The authors are thankful to the Institute of Brain Chemistry and Human Nutrition and the Mother and Child Foundation for financial coverage of the fatty acid chromatographic analyses.

Conflict of interest:

The authors declare no conflict of interest.

Acknowledgements:

The authors thank Mr Mauro Cardoso Pereira for the care provided to the rats.

Authors contributions:

RLHW, AAB and EBR conceptualized the study. All authors have substantially contributed to the acquisition, analysis and interpretation of results. All authors contributed to manuscript write-up. All authors have approved the version to be published and are equally accountable for all aspects of this work.

BIBLIOGRAPHY

- membranes. Trends in Biochemical Sciences 1985; 10:418-21.
- 2. Yeagle PL. Lipid regulation of cell membrane structure and function. The FASEB journal. 1989; 3:1833-42.
- 3. Jumpsen J, Clandinin M. Lipids and Essential Fatty Acids in dietary lipid and lipid metabolism. New York: The American Oil Chemists Society Publishing, pag. 30,1995.
- 4. Berg JM, Tymoczko JL, Stryer L. Elongation and Unsaturation of Fatty Acids Are Accomplished by Accessory Enzyme Systems. En Biochemistry, 5th edition. New York: WH 21. Martin CA, Visentainer JV, de Oliveira CC, Matsushita M, Freeman, section 22.6, 2002.
- 5. Santos HO, Price JC, Bueno AA. Beyond Fish Oil Supplementation: The Effects of Alternative Plant Sources of 22. Eaton SB, Eaton SB 3rd, Sinclair AJ, Cordain L, Mann Omega-3 Polyunsaturated Fatty Acids upon Lipid Indexes and Cardiometabolic Biomarkers-An Overview. Nutrients. 2020; 16;12:3159.
- 6. Sprecher H, Chen Q, Yin FQ. Regulation of the biosynthesis of 22:5n-6 and 22:6n-3: a complex intracellular process. Lipids. 1999; 34:S153-S156.
- 7. Uauy R, Mena P, Wegher B, Nieto S, Salem N Jr. Long chain polyunsaturated fatty acid formation in neonates: effect of gestational age and intrauterine growth. Pediatr Res. 2000; 25. Morales, L. Emilio, Angie H. "Is fish worth more than 47:127-35.
- 8. Plourde M, Cunnane SC. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary appears in Appl Physiol Nutr Metab 2008 33(1):228-9]. Appl Physiol Nutr Metab. 2007; 32:619-34.
- RA. Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr. 1994; 60:189-94.
- temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem Res. 2010; 35:503-13.
- 11. Dornellas AP, Watanabe RL, Pimentel GD, et al. Deleterious 29. effects of lard-enriched diet on tissues fatty acids composition and hypothalamic insulin actions. Prostaglandins Leukot Essent Fatty Acids. 2015; 102-103:21-29.
- 12. Lawson H. Sources of Oils and Fats. En Food Oils and Fats. Springer, Boston, MA, pag. 39-48, 1995.
- impaired kidney function and chronic kidney disease. Am J Physiol Renal Physiol. 2011; 301:F919-F931.
- 14. Ruiz-Núñez B, Pruimboom L, Dijck-Brouwer DA, Muskiet FA. Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context. J Nutr 33. Biochem. 2013; 24:1183-201.
- 15. Tennant D, Gosling JP. Modelling consumer intakes of vegetable oils and fats. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2015; 32:1397-405.
- 16. Kim J, Kim DN, Lee SH, Yoo SH, Lee S. Correlation of fatty acid composition of vegetable oils with rheological behaviour

- and oil uptake. Food Chemistry. 2010; 118:398-402.
- 1. Storch J, Kleinfeld AM. The lipid structure of biological 17. Alves AQ, da Silva VA Jr, Góes AJS, et al. The Fatty Acid Composition of Vegetable Oils and Their Potential Use in Wound Care. Adv Skin Wound Care. 2019; 32:1-8.
 - https://www.indexmundi.com/agriculture/?commodity=so ybean-meal&graph=domestic-consumption.
 - Brain Development. En Brain Development: relationship to 19. https://www.census.gov/popclock/print.php?component=c ounter
 - **Gupta SK.** Breeding Oilseed Crops for Sustainable Production: Opportunities and Constraints. Elsevier Academic Press 2016; ISBN 978-0-12-801309-0.
 - de Souza NE. Trans polyunsaturated fatty acid contents in Brazilian refined soybean oil. Anal Sci. 2006; 22:631-33.
 - NJ.Dietary intake of long-chain polyunsaturated fatty acids during the paleolithic. World Rev Nutr Diet. 1998; 83:12-23.
 - 23. Siscovick DS, Raghunathan T, King I, et al. Dietary intake of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. Am J Clin Nutr. 2000; 71:208S-12S.
 - 24. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc. 2005; 105:428-40.
 - meat?-How consumers' beliefs about health and nutrition affect their willingness to pay more for fish than meat." Food Quality and Preference. 2018 65:101-09.
 - essentiality and use as supplements [published correction 26. Jeffrey A. Hutchings, John D. Reynolds. Marine Fish Population Collapses: Consequences for Recovery and Extinction Risk. BioScience. 2004; 54:297-309.
- 9. Makrides M, Neumann MA, Byard RW, Simmer K, Gibson 27. Li D, Hu X. Fish and its multiple human health effects in times of threat to sustainability and affordability: are there alternatives? Asia Pacific Journal of Clinical Nutrition. 2009; 18:553.
- 10. Fraser T, Tayler H, Love S. Fatty acid composition of frontal, 28. Greene J, Ashburn SM, Razzouk L, Smith DA. Fish oils, coronary heart disease, and the environment. Am J Public Health. 2013; 103:1568-76.
 - Lenihan-Geels G, Bishop KS, Ferguson LR. Alternative sources of omega-3 fats: can we find a sustainable substitute for fish? Nutrients. 2013; 5:1301-15.
 - 30. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood). 2008; 233:674-88.
- 13. Odermatt A. The Western-style diet: a major risk factor for 31. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011; 44:203-15.
 - 32. Huang CW, Chien YS, Chen YJ, Ajuwon KM, Mersmann HM, Ding ST. Role of n-3 Polyunsaturated Fatty Acids in Ameliorating the Obesity-Induced Metabolic Syndrome in Animal Models and Humans. Int J Mol Sci. 2016; 17:1689.
 - Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 7:CD003177.
 - 34. Sokoła-Wysoczańska E, Wysoczański T, Wagner J, et al. Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in Cardiovascular System Disorders-A Review. Nutrients.

- 2018; 10:1561.
- 35. Raygan F, Taghizadeh M, Mirhosseini N, et al. A comparison between the effects of flaxseed oil and fish oil supplementation on cardiovascular health in type 2 diabetic patients with 52. coronary heart disease: A randomized, double-blinded, placebo-controlled trial. Phytother Res. 2019; 33:1943-51.
- 36. Morshedzadeh N, Shahrokh S, Aghdaei HA, et al. Effects of flaxseed and flaxseed oil supplement on serum levels of disease in patients with ulcerative colitis. Complement Ther Med. 2019; 46:36-43.
- Amirmoezi F, Azimi A. Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients: a randomized, doubleblind, placebo-controlled trial. Nutr Diabetes. 2017; 7(4):e259.
- 38. Bamberger C, Rossmeier A, Lechner K, et al. A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, 55. European Food Safety Authority Outcome of the Public Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial. Nutrients. 2017; 9(10):1097.
- 39. Fenwick N, Griffin G, Gauthier C. The welfare of animals used in science: how the "Three Rs" ethic guides improvements. 56. Poggetti L, Ferfuia C, Chiabà C, Testolin R, Baldini M. Can Vet J. 2009; 50:523-30.
- 40. Bueno AA, Brand A, Neville MM, Lehane C, Brierley N, Crawford MA. Erythrocyte phospholipid molecular species affected siblings. Br J Nutr. 2015; 113:72-81.
- 41. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome 58. and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105:141-50.
- 42. Montecucco F, Liberale L, Bonaventura A, Vecchiè A, Dallegri F, Carbone F. The Role of Inflammation in Cardiovascular Outcome. Curr Atheroscler Rep. 2017; 19:11.
- 43. Oliveira BCL, Bellozi PMQ, Reis HJ, de Oliveira ACP.Inflammation as a Possible Link Between Dyslipidemia and Alzheimer's Disease. Neuroscience. 2018; 376:127-41.
- 44. Rosenberg GA. Extracellular matrix inflammation in vascular 60. Carrié I, Clément M, de Javel D, Francès H, Bourre JM. cognitive impairment and dementia. Clin Sci (Lond). 2017; 131:425-37.
- 45. Kruk ME, Nigenda G, Knaul FM. Redesigning primary care to tackle the global epidemic of noncommunicable disease. Am 61. J Public Health. 2015; 105:431-437.
- 46. Chen S, Kuhn M, Prettner K, Bloom DE. The macroeconomic burden of noncommunicable diseases in the United States: Estimates and projections. PLoS One. 2018; 13(11):e0206702.
- women. J Am Med Womens Assoc. 1972; 46:126-130.
- 48. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab. 2003; Disord 27 Suppl 3:S49-S52.
- 49. Lands B. Consequences of essential fatty acids. Nutrients. 2012; 4:1338-57.
- 50. Sanders TA. Polyunsaturated fatty acids in the food chain in 64. Europe Am J Clin Nutr. 2000; 71(1 Suppl):176S-8S.

- 51. Odermatt A. The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease. Am J Physiol Renal Physiol. 2011; 301:F919-F931.
- Orsavova J, Misurcova L, Ambrozova JV, Vicha R, Mlcek J. Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. Int J Mol Sci. 2015; 16:12871-90.
- inflammatory markers, metabolic parameters and severity of 53. Ahmed AA, Celi B, Ronald K, Holub BJ. The phospholipid and fatty acid compositions of seal platelets: a comparison with human platelets. Comp Biochem Physiol B. 1989; 93:119-23.
- 37. Zibaeenezhad MJ, Farhadi P, Attar A, Mosleh A, 54. European Food Safety Authority Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal. 2010; 8:1461.
 - Consultation on the Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition, and Allergies (NDA).On establishing Food-Based Dietary Guidelines. EFSA Journal. 2010; 8:1506.
 - Kernel oil content and oil composition in walnut (Juglans regia L.) accessions from north-eastern Italy. J Sci Food Agric. 2018; 98:955-62.
 - and fatty acids of Down syndrome children compared with non- 57. Lozano A, Perez-Martinez P, Marin C, et al. An acute intake of a walnut-enriched meal improves postprandial adiponectin response in healthy young adults. Nutr Res. 2013; 33:1012-8.
 - West SG, Krick AL, Klein LC, et al. Effects of diets high in walnuts and flax oil on hemodynamic responses to stress and vascular endothelial function. J Am Coll Nutr.2010; 29:595-603.
 - 59. Katz DL, Davidhi A, Ma Y, Kavak Y, Bifulco L, Njike VY. Effects of walnuts on endothelial function in overweight adults with visceral obesity: a randomized, controlled, crossover trial. JAm Coll Nutr. 2012; 31:415-23.
 - Specific phospholipid fatty acid composition of brain regions in mice. Effects of n-3 polyunsaturated fatty acid deficiency and phospholipid supplementation. J Lipid Res. 2000; 41:465-72.
 - Brenna JT, Salem N Jr, Sinclair AJ, Cunnane SC; International Society for the Study of Fatty Acids and Lipids, Alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009; 80:85-91.
- 47. Schapira DV. Diet, obesity, fat distribution and cancer in 62. Lin YH, Llanos A, Mena P, Uauy R, Salem N Jr, Pawlosky RJ. Compartmental analyses of 2H5-alpha-linolenic acid and C-U-eicosapentaenoic acid toward synthesis of plasma labeled 22:6n-3 in newborn term infants. Am J Clin Nutr. 2010; 92:284-93.
 - 63. Lane K, Derbyshire E, Li W, Brennan C. Bioavailability and potential uses of vegetarian sources of omega-3 fatty acids: a review of the literature. Crit Rev Food Sci Nutr. 2014; 54:572-9.
 - Wada M, DeLong CJ, Hong YH, et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived

- versus eicosapentaenoic acid-derived substrates and products. J Biol Chem. 2007; 282:22254-66.
- 65. **Lands B.** Dietary omega-3 and omega-6 fatty acids compete in producing tissue compositions and tissue responses. Mil Med. 2014; 179:76-81.
- 66. Li D, Weisinger HS, Weisinger RS, et al. Omega 6 to omega 3 fatty acid imbalance early in life leads to persistent reductions in DHA levels in glycerophospholipids in rat hypothalamus even after long-term omega 3 fatty acid repletion. Prostaglandins Leukot Essent Fatty Acids. 2006; 74:391-9.
- 67. Kuipers RS, Luxwolda MF, Janneke Dijck-Brouwer DA, Muskiet FA. Intrauterine, postpartum and adult relationships between arachidonic acid (AA) and docosahexaenoic acid (DHA). Prostaglandins Leukot Essent Fatty Acids. 2011; 85:245-52.
- 68. Luxwolda MF, Kuipers RS, Sango WS, Kwesigabo G, Dijck-Brouwer DA, Muskiet FA. A maternal erythrocyte DHA content of approximately 6 g% is the DHA status at which intrauterine DHA biomagnifications turns into bioattenuation and postnatal infant DHA equilibrium is reached. Eur J Nutr. 2012; 51:665-75.
- 69. **Schlörmann W, Kramer R, Lochner A, et al.** Foetal cord blood contains higher portions of n-3 and n-6 long-chain PUFA but lower portions of trans C18:1 isomers than maternal blood. Food Nutr Res. 2015; 59:29348.

